Free Trial

Enovis (ENOV) Competitors

Enovis logo
$30.60 -0.42 (-1.36%)
Closing price 03:59 PM Eastern
Extended Trading
$30.66 +0.07 (+0.22%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ENOV vs. DOV, STVN, IRTC, GKOS, BLCO, TMDX, SLNO, NVST, LIVN, and WRBY

Should you be buying Enovis stock or one of its competitors? The main competitors of Enovis include Dover (DOV), Stevanato Group (STVN), iRhythm Technologies (IRTC), Glaukos (GKOS), Bausch + Lomb (BLCO), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Envista (NVST), LivaNova (LIVN), and Warby Parker (WRBY).

Enovis vs. Its Competitors

Dover (NYSE:DOV) and Enovis (NYSE:ENOV) are related companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

In the previous week, Dover had 5 more articles in the media than Enovis. MarketBeat recorded 18 mentions for Dover and 13 mentions for Enovis. Dover's average media sentiment score of 1.52 beat Enovis' score of 1.42 indicating that Dover is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dover
16 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Enovis
8 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Dover has higher revenue and earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Dover, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dover$7.75B3.22$2.70B$16.5810.95
Enovis$2.11B0.83-$825.49M-$14.25-2.15

Dover presently has a consensus target price of $213.92, suggesting a potential upside of 17.78%. Enovis has a consensus target price of $51.00, suggesting a potential upside of 66.68%. Given Enovis' stronger consensus rating and higher probable upside, analysts clearly believe Enovis is more favorable than Dover.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dover
0 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.58
Enovis
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

84.5% of Dover shares are held by institutional investors. Comparatively, 98.5% of Enovis shares are held by institutional investors. 1.3% of Dover shares are held by insiders. Comparatively, 2.7% of Enovis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Dover has a net margin of 29.29% compared to Enovis' net margin of -37.80%. Dover's return on equity of 18.19% beat Enovis' return on equity.

Company Net Margins Return on Equity Return on Assets
Dover29.29% 18.19% 9.86%
Enovis -37.80%6.78%3.73%

Dover has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Enovis has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500.

Summary

Dover beats Enovis on 11 of the 16 factors compared between the two stocks.

Get Enovis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENOV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENOV vs. The Competition

MetricEnovisMEDICAL INFO SYS IndustryMedical SectorNYSE Exchange
Market Cap$1.77B$2.13B$5.78B$21.31B
Dividend YieldN/AN/A3.95%3.51%
P/E Ratio-2.1537.4631.2629.34
Price / Sales0.839.66454.1352.84
Price / Cash1.6152.6337.7323.86
Price / Book0.686.5910.045.39
Net Income-$825.49M-$63.67M$3.27B$996.59M
7 Day Performance3.95%3.23%3.17%3.12%
1 Month Performance11.83%0.62%4.34%2.97%
1 Year Performance-32.49%28.23%44.12%12.83%

Enovis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENOV
Enovis
4.5371 of 5 stars
$30.60
-1.4%
$51.00
+66.7%
-31.7%$1.77B$2.11B-2.157,367Positive News
Insider Trade
DOV
Dover
4.9488 of 5 stars
$180.53
-1.4%
$213.92
+18.5%
+0.2%$25.11B$7.75B10.8924,000Positive News
STVN
Stevanato Group
1.7841 of 5 stars
€21.99
-2.8%
N/A+9.2%€6.66B€1.19B40.725,521News Coverage
Positive News
IRTC
iRhythm Technologies
1.345 of 5 stars
$165.68
-2.0%
$162.64
-1.8%
+149.9%$5.43B$591.84M-56.552,000Positive News
Analyst Forecast
GKOS
Glaukos
4.7232 of 5 stars
$91.78
-2.5%
$127.42
+38.8%
-29.5%$5.40B$383.48M-55.62780Analyst Revision
BLCO
Bausch + Lomb
1.1889 of 5 stars
$14.57
-2.5%
$15.56
+6.8%
-10.2%$5.29B$4.79B-18.6713,500
TMDX
TransMedics Group
2.888 of 5 stars
$114.97
-4.1%
$123.00
+7.0%
-33.3%$4.09B$441.54M59.57210Positive News
Analyst Forecast
SLNO
Soleno Therapeutics
4.5705 of 5 stars
$66.51
-3.0%
$115.09
+73.0%
+38.0%$3.64BN/A-16.0730News Coverage
Analyst Forecast
NVST
Envista
3.6053 of 5 stars
$21.15
-2.6%
$20.92
-1.1%
+13.6%$3.61B$2.51B66.1012,300Positive News
LIVN
LivaNova
1.618 of 5 stars
$56.35
+0.8%
$59.71
+6.0%
+21.2%$3.05B$1.25B-14.492,900Positive News
WRBY
Warby Parker
2.1624 of 5 stars
$26.18
-3.1%
$24.06
-8.1%
+72.7%$2.84B$771.32M-373.883,780Positive News

Related Companies and Tools


This page (NYSE:ENOV) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners